Global Stem Cell Therapy Market

Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Companies Covered
    230

  • Pages
    382

  • View Count
    15949

Stem Cell Therapy Market Overview

The global stem cell therapy market for cardiovascular and metabolic disorders is likely to grow to $3.3 billion by 2030, driven by the rising incidence of these disorders. Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders.  In the US, the annual economic burden associated with these disorders is estimated to be over USD 500 billion. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs are expected to be over USD 1 trillion by 2035. Despite considerable advances in healthcare, most of the currently available treatment options for cardiovascular disorders focus on palliative care and cannot actually repair damaged cardiac tissue. Although heart transplant is a viable option to treat complex cardiovascular conditions, the waiting time associated with this alternative is excruciatingly long.

Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. In 2017, it was estimated that 425 million individuals, between the ages 20 years to 79 years, were living with diabetes across the globe, and this number is expected to increase substantially in the foreseen future. Similar to cardiovascular diseases, most of the current treatment options for metabolic disorders are indicated for only controlling / managing disease related symptoms.

The context of stem cell therapy market report, published by Roots Analysis This image highlights the unmet needs in stem cell therapy domain List of stem cell therapies for cardiovascular and metabolic disorders from the research report of Roots Analysis

Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders. The field of regenerative medicine has evolved substantially in the recent past; the first stem cell therapy, called Cellgram®-AMI (2011), was approved by the Ministry of Foods and Drug Safety of Korea, for the treatment of acute myocardial infarction. Presently, two other stem cell-based treatment options, namely HeartSheet (heart failure, 2015) and Stempeucel (critical limb ischemia, 2017), are commercially available for cardiovascular disorders. For metabolic disorders, most stem cell therapy candidates are still under development. However, there is one approved product, called Strimvelis for ADA-SCID (2016). Several stakeholders are engaged in efforts to advance the development of regenerative therapies for both cardiovascular and metabolic disorders. In fact, venture capital (VC) firms and government bodies are actively funding several such ongoing research initiatives.

Recent Developments in Stem Cell Therapy Market:

Several recent developments have taken place in the field of stem cell therapy market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, BioLineRx announced the FDA approval of Motixafortide Plus  Filgrastim for stem cell mobilization in patients suffering from multiplr myeloma.  
  • In August 2023, BlueRock Therapeutics entered into a research collaboration with bit.bio in order to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. 
  • In August 2023, a research article published in the New England Journal of Medicine revealed that stem cell gene therapy might have the potential for the treatment of Sickle Cell Disease (SCD). The data is backed by the Novartis’ Phase I/II clinical trial for the use of cryopreserved stem cells to reduce vaso-constriction.

Key Companies in Global Stem Cell Therapy Market 

Examples of key companies engaged in global stem cell therapy market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Stempeutics Research, Cesca Therapeutics, BioCardia, Caladrius Biosciences, Mesoblast, Pluristem Therapeutics, Orchard Therapeutics, Global Cell Med, Longeveron and Tianhe Stem Cell Biotechnologies . This market report includes an easily searchable excel database of all the companies developing stem cell therapy for cardiovascular and metabolic disorders, worldwide.

Scope of the Report

The “Global Stem Cell Therapy Market: Focus on Cardiovascular and Metabolic Disorders, 2019-2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the stem cell therapy market. The market research report includes all stem cell therapies that are being developed for the treatment of cardiovascular and metabolic disorders. In addition, we have provided a list of stem cell therapies being developed for stroke, a condition associated with vasculature in the brain.

Current market landscape of stem cell therapy domain, prepared by Roots Analysis Competitive analysis of stem cell therapies, from Roots Analysis report This image provides information on investments received by the companies engaged in stem cell therapies development

Amongst other elements, the market research report features the following:

  • A detailed assessment of the current market landscape of stem cell therapies with respect to target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indications (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent and embryonic pluripotent), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary and implantation).
  • An analysis highlighting the key unmet needs across cardiovascular and metabolic disorders, featuring insights generated from social media posts, recent scientific publications, patient blogs and the views of contemporary key opinion leaders as expressed on online platforms.
  • An overview of the focus areas of therapy developers, including an assessment of the existing opportunity for stem cell therapies across diverse therapeutic indications.
  • An insightful company competitiveness analysis featuring a three-dimensional bubble representation, highlighting the key players in stem cell therapy market on the basis of the strength of their respective product portfolios, taking into consideration the number of therapies under development, phase of development of these therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.
  • An analysis of the partnerships that have been established in stem cell therapy market in the period 2012-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, capital raised from IPOs / secondary offerings, debt financing and grants.
  • An analysis of contemporary peer-reviewed scientific research articles published during the period 2013-2018, highlighting the key focus areas of the ongoing research activity, in terms of therapeutic area, target disease indication, and stem cell lineages.
  • Comprehensive profiles of approved and late stage clinical products; each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on recommended dose, price and manufacturing process (wherever available).

The key objective of stem cell therapy market report is to provide a detailed stem cell therapy market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for stem cells market during the forecast period. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2019-2030. The market report includes information on (potential) sales-based revenues generated by stem cell therapies that are currently marketed or are in late stages of development for the treatment of cardiovascular and metabolic disorders. Additionally, it presents details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic areas (cardiovascular and metabolic), [B] target disease indications (myocardial infarction, heart failure, critical limb ischemia, diabetes, ADA-SCID,  metachromatic leukodystrophy, and other cardiovascular and metabolic disorders ), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and implantation) and [G] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

This image highlights the partnership activity undertaken by players engaged in stem cell therapies domain The current and future market trends of stem cell therapies according to Roots Analysis The market segments of stem cell therapies domain based on the research report of Roots Analysis

The opinions and insights presented in this market research were influenced by discussions conducted with several key players in stem cell therapy market. The market report features detailed transcripts of interviews held with the following individuals:

  • Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
  • Dr. William L. Rust (Founder and Chief Executive Officer, Seraxis)
  • Xuejun H. Parsons (Chief Executive Officer, Xcelthera)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is stem cell therapy?

Answer: Stem cell therapy, involves engineering of human stem cells to develop or regenerate tissues or organs.

Question 2: How big is the global stem cell therapy market for cardiovascular and metabolic disorders?

Answer: The global stem cell therapy market size for cardiovascular and metabolic disorders is estimated to reach $3.3 billion by 2030.

Question 3: Who are the leading companies in the global stem cell therapy market for cardiovascular and metabolic disorders?

Answer: Examples of key companies engaged in global stem cell therapy market for cardiovascular and metabolic disorders (which have also been profiled in this market report; the complete list of companies is available in the full report) include Stempeutics Research, Cesca Therapeutics, BioCardia, Caladrius Biosciences, Mesoblast, Pluristem Therapeutics, Orchard Therapeutics, Global Cell Med, Longeveron and Tianhe Stem Cell Biotechnologies .

Question 4: How many stem cell therapies are currently under development for cardiovascular and metabolic disorders?

Answer: Presently, over 60 stem cell therapies are under development for cardiovascular and metabolic disorders.

Question 5: How much money has been invested by stakeholders in the global stem cell therapy market for cardiovascular and metabolic disorders?

Answer: Till date, over USD 2 billion has been invested by stakeholders in the global stem cell therapy market for cardiovascular and metabolic disorders, highlighting the growing opportunities within the industry.

Question 6: How many research articles related to the global stem cell therapy market for cardiovascular and metabolic disorders have been published over the last few years?

Answer: Since 2013, more than 150 research articles related to the global stem cell therapy market for cardiovascular and metabolic disorders have been published.

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
click for sending an email to Roots Analysis team sales@rootsanalysis.com